168 related articles for article (PubMed ID: 27220960)
21. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Cainap C; Qin S; Huang WT; Chung IJ; Pan H; Cheng Y; Kudo M; Kang YK; Chen PJ; Toh HC; Gorbunova V; Eskens FA; Qian J; McKee MD; Ricker JL; Carlson DM; El-Nowiem S
J Clin Oncol; 2015 Jan; 33(2):172-9. PubMed ID: 25488963
[TBL] [Abstract][Full Text] [Related]
22. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
Tsuchiya K; Asahina Y; Matsuda S; Muraoka M; Nakata T; Suzuki Y; Tamaki N; Yasui Y; Suzuki S; Hosokawa T; Nishimura T; Ueda K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Izumi N
Cancer; 2014 Jan; 120(2):229-37. PubMed ID: 24122122
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
Cardin DB; Goff L; Li CI; Shyr Y; Winkler C; DeVore R; Schlabach L; Holloway M; McClanahan P; Meyer K; Grigorieva J; Berlin J; Chan E
Cancer Med; 2014 Jun; 3(3):572-9. PubMed ID: 24574334
[TBL] [Abstract][Full Text] [Related]
24. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
Ikeda M; Shimizu S; Sato T; Morimoto M; Kojima Y; Inaba Y; Hagihara A; Kudo M; Nakamori S; Kaneko S; Sugimoto R; Tahara T; Ohmura T; Yasui K; Sato K; Ishii H; Furuse J; Okusaka T
Ann Oncol; 2016 Nov; 27(11):2090-2096. PubMed ID: 27573564
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Lim HY; Heo J; Choi HJ; Lin CY; Yoon JH; Hsu C; Rau KM; Poon RT; Yeo W; Park JW; Tay MH; Hsieh WS; Kappeler C; Rajagopalan P; Krissel H; Jeffers M; Yen CJ; Tak WY
Clin Cancer Res; 2014 Dec; 20(23):5976-85. PubMed ID: 25294897
[TBL] [Abstract][Full Text] [Related]
27. Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib.
Zheng J; Shao G; Luo J
Clin Transl Oncol; 2014 Nov; 16(11):1012-7. PubMed ID: 24894839
[TBL] [Abstract][Full Text] [Related]
28. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
[TBL] [Abstract][Full Text] [Related]
29. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
Negri FV; Dal Bello B; Porta C; Campanini N; Rossi S; Tinelli C; Poggi G; Missale G; Fanello S; Salvagni S; Ardizzoni A; Maria SE
Liver Int; 2015 Aug; 35(8):2001-8. PubMed ID: 25559745
[TBL] [Abstract][Full Text] [Related]
30. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Kelley RK; Nimeiri HS; Munster PN; Vergo MT; Huang Y; Li CM; Hwang J; Mulcahy MF; Yeh BM; Kuhn P; Luttgen MS; Grabowsky JA; Stucky-Marshall L; Korn WM; Ko AH; Bergsland EK; Benson AB; Venook AP
Ann Oncol; 2013 Jul; 24(7):1900-1907. PubMed ID: 23519998
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
32. Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
Lee FA; Zee BC; Cheung FY; Kwong P; Chiang CL; Leung KC; Siu SW; Lee C; Lai M; Kwok C; Chong M; Jolivet J; Tung S
Am J Clin Oncol; 2016 Dec; 39(6):609-613. PubMed ID: 24977690
[TBL] [Abstract][Full Text] [Related]
33. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
[TBL] [Abstract][Full Text] [Related]
34. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
Srimuninnimit V; Sriuranpong V; Suwanvecho S
Asia Pac J Clin Oncol; 2014 Sep; 10(3):255-60. PubMed ID: 24810940
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
Abdel-Rahman O; Abdelwahab M; Shaker M; Abdelwahab S; Elbassiony M; Ellithy M
J Egypt Natl Canc Inst; 2014 Mar; 26(1):9-13. PubMed ID: 24565677
[TBL] [Abstract][Full Text] [Related]
38. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
39. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.
Cheng AL; Thongprasert S; Lim HY; Sukeepaisarnjaroen W; Yang TS; Wu CC; Chao Y; Chan SL; Kudo M; Ikeda M; Kang YK; Pan H; Numata K; Han G; Balsara B; Zhang Y; Rodriguez AM; Zhang Y; Wang Y; Poon RT
Hepatology; 2016 Sep; 64(3):774-84. PubMed ID: 27082062
[TBL] [Abstract][Full Text] [Related]
40. S-1 plus sorafenib for the treatment of advanced hepatocellular carcinoma.
Huang W; You L; Liu D; Yang S; Liu M; Wang H; Wang P; Baikere P; Gu P; Abulikemu A; Yuan S; Fan X
J BUON; 2016; 21(6):1388-1393. PubMed ID: 28039697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]